At what enterprise value was DUTSCHER acquired in 2026?

During the acquisition of DUTSCHER by VIVO CAPITAL in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DUTSCHER when it was acquired by VIVO CAPITAL?

The estimated EV/EBITDA multiple for DUTSCHER is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was DUTSCHER acquired by VIVO CAPITAL?

DUTSCHER was acquired by VIVO CAPITAL in 2026.

What was the revenue of DUTSCHER at the time of the deal?

The revenue of DUTSCHER at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of DUTSCHER during the acquisition?

DUTSCHER's EBITDA is estimated to be in the range of 10M - 30M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DUTSCHER acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DUTSCHER deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/sortie/lbo-france-cede-dutscher-a-vivo-capital-pour-pres-de-250-meur-2213727

← DATABASE

Home Database Healthcare & PharmaDUTSCHER

02/2026

DUTSCHER acquired by VIVO CAPITAL

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 300M - 700M EUR

Context

Vivo Capital acquired a majority stake in Dutscher from LBO France. LBO France had acquired the asset in July 2020 from Five Arrows (Rothschild) for an enterprise value of EUR100-150M (investing EUR60M in equity). In this exit, LBO France achieved a net return multiple of ~2.5x. Interestingly, Five Arrows remains involved as the debt provider for this new LBO. The deal is expected to close in H1 2026.

Historically, the company has undergone several LBOs, notably led by Five Arrows in 2014 and Lbo France in 2020. These multiple LBO cycles illustrate the strong interest in this type of asset.

DUTSCHER, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Alsace, Dutscher is a leading European distributor of consumables (pipettes, reagents) and equipment for research and medical laboratories. The company acts as a "one-stop-shop" for public research institutes and biotech companies. Under LBO France's ownership (2020-2026), Dutscher transformed from a French-centric player into a pan-European platform. It completed 13 add-on acquisitions ("build-ups"), expanding its footprint into the Nordics (Denmark, Sweden, Finland), the Baltics, and strengthening its presence in the UK/Ireland.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Other operations with DUTSCHER

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2020	LBO FRANCE	DUTSCHER	FRANCE	Life Sciences	LBO France acquired a controlling stake in Dutscher, replacing Five Arrows (who had held the majority since 2014). This Secondary LBO also marked the exit of the founder's son, who held ~40% but had no operational role, completing the transition from a family-owned business to a financial-backed platform.
01/2014	FIVE ARROWS	DUTSCHER	FRANCE	Life Sciences	Five Arrows Managers acquired a stake in Dominique Dutscher to facilitate a partial cash-out for the founder, Dominique Dutscher. While the exact percentage was undisclosed at the time, the deal structure was a classic Owner Buy-Out (OBO), allowing the founder to secure some wealth while remaining invested to drive the next phase of growth. The transaction was financed with senior debt provided by a pool of three banks.

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DUTSCHER by VIVO CAPITAL are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: vivo capital